Crestor is a powerful drug used to treat high cholesterol. However, it can have some unexpected side effects that patients may not be aware of.

The FDA is providing up-to-date information about the risk of serious muscle damage, called rhabdomyolysis, in patients taking Crestor as well as similar drugs, called statins. This is a well-known, rare side effect of all statins. Rhabdomyolysis is a condition in which muscle cells break down. This floods the blood with muscle proteins, sometimes leading to fatal kidney failure.

The FDA has issued a public health advisory to further explain the risks and benefits of the cholesterol-lowering drug Crestor. The drug will now carry a new label that includes new recommended doses for patients at a higher risk of muscle damage, including Asian patients.

"The FDA is committed to providing Americans with the latest and most comprehensive information on the medicines they use," says Steven Galson, MD, MPH, acting director of the Center for Drug Evaluation and Research (CDER). “An FDA advisory on Crestor is part of an ongoing effort to notify the public of potentially significant emerging safety data so that they can make more informed choices about their medical care."

In June 2004, the FDA advised doctors to be careful about how they prescribe Crestor. In January 2005, Crestor's manufacturer, AstraZeneca Pharmaceuticals, reported that a patient died while taking Crestor.

The FDA says extensive review of the large amount of available data indicates that patients taking recommended doses of Crestor have a similar risk of rhabdomyolysis as patients taking other statin drugs. Other available statins include Lipitor, Pravachol, and Zocor.

Crestor's manufacturer is also reminding doctors that they should consider using lower starting doses of Crestor in some individuals. However, this does not eliminate the risk for serious side effects.

If you feel that you or a loved one has experienced harmful side effects while taking Crestor, contact us today to find out if you may have a personal injury claim.

  • Cylert (pemoline) was a drug used for attention deficit hyperactivity disorder for thirty years before it was discontinued.

    In some patients pemoline has been suspected of causing hepatotoxicity (liver toxicity), so the FDA recommended that regular liver tests should be performed on those treated with it.

    Despite attempted efforts to make doctors and patients aware of the risk, the drug has been linked with a number of cases of liver failure, of which 13 resulted in liver replacement or death.

  • Darvocet is a powerful painkiller that combined the opioid drug dextropropoxyphene with acetaminophen. It was removed from the market due to a variety of unforeseen side effects.

    One of the primary risks of Darvocet was the fact that it contained acetaminophen. Overdose of acetaminophen could happen all too easily, leading to potentially fatal liver toxicity.

  • Duragesis pain patches are a delivery method of the painkiller fentanyl that are able to provide up to three days' relief from severe chronic pain, such as that experienced by bone cancer patients. However, the active ingredient, as well as faulty construction of the patches themselves led to serious risks to patients and an FDA ban.

    Dozens of overdoses and deaths were linked to use of Duragesic patches before they were pulled from the market. An overdose of the morphine-like drug can put a patient into a coma and shut down breathing.

  • Eczema, also called atopic dermatitis is painful and troublesome form of skin inflammation. One major type of drug used to treat this condition is the topical immunosuppressant. This category of medication is applied to the skin of patients who do not respond to steroids.

    Two specific drugs, Elidel (pimecrolimus) and Protopic (tacrolimus), approved for treatment of eczema, are not without controversy. They have been closely associated with a possible cancer risk in studies done on animals.

  • Antidepressant drugs such as Effexor (venlafaxine) have been shown to increase the chance of suicidal thoughts and attempts in adults under age 25, while reducing the risk among older adults. Effexor is licensed for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder and social phobia.

    The risk of suicidal thinking or attempts is 62 percent higher among the young adults enrolled in clinical trials of antidepressants, compared with patients taking placebos, Food and Drug Administration staff has said. On the other hand, among adults over 25, the risk of suicidal thinking declines by 21 percent.

  • Enteryx is an injection used to treat gastroesophageal reflux disease (GERD). GERD is a chronic digestive disease where stomach acid flows back into the esophagus irritating its lining.

    Enteryx is injected as a liquid that solidifies into a spongy material that cannot be removed. When it is injected properly, it strengthens the lower esophagus, helping prevent stomach acid from entering it and causing pain.

  • Ephedra is an herbal stimulant that was used as a dietary supplement for both weight loss and athletic performance enhancement. However, it was linked to heart attacks, strokes and other health problems, which ultimately led to its ban by the Food and Drug Administration (FDA).

    Products containing ephedra and ephedra extract, also known as ma-huang, were widely promoted for losing weight and enhancing physical performance, with its popularity peaking in the early 2000s.

  • Letrozole is a drug approved for use only in postmenopausal women with breast cancer. But there is evidence some doctors have prescribed it as a fertility treatment because it suppresses estrogen and can promote ovulation. It is marketed under the name Femara.

    The manufacturer of a breast cancer drug, letrozole, has warned fertility doctors that it has been associated with birth defects, a caution prompted by reports that the drug was being used to help a woman become pregnant.

    Swiss drug manufacturer Novartis sent letters to fertility doctors worldwide to reiterate a warning that the drug should not be given to women who may be pregnant.

  • Fenfluramine/Phentermine, commonly called Fen-Phen, is a powerful diet drug that was taken by millions of Americans to combat obesity.

    However, clinical research showed that the fenfluramine portion of the combination can cause heart disease in otherwise healthy patients.

    Studies concluded that this drug could cause potentially fatal pulmonary hypertension and heart valve problems, which led to its eventually being pulled from the market.

    Though efforts were made to ensure that doctors no longer prescribed this harmful substance, many people were put at risk by this powerful drug.

  • Fosamax is an oral biphosphonate prescribed to millions of osteoporosis sufferers over the years. It is supposed to increase bone density by slowing down the body’s process of bone breakdown over time.

    However, researchers have now found that this drug can actually cause bones to weaken and crumble.